Investor Relations
Investor Relations
Corporate Profile
Allogene Therapeutics is a clinical stage biotechnology company leading the development of allogeneic chimeric antigen receptor T cell (AlloCAR T™) therapies for cancer. Led by a management team with significant experience in cell therapy, we are developing a pipeline of “off-the-shelf” CAR T cell therapy candidates with the goal of delivering readily available cell therapy faster, more reliably, and at greater scale to more patients.
Data Provided by Refinitiv. Minimum 15 minutes delayed.
News Releases
Jan 11
2022
2022
Allogene Therapeutics Announces Exclusive Collaboration and Global License Agreement with Antion Biosciences for Multiplex miCAR™ Technology
Learn More >
Jan 10
2022
2022
Allogene Therapeutics Announces Removal of FDA Clinical Hold Across All AlloCAR T™ Clinical Trials
Learn More >
Jan 04
2022
2022
Allogene Therapeutics to Present at the Virtual 40th Annual J.P. Morgan Healthcare Conference
Learn More >
Dec 15
2021
2021
Allogene Therapeutics Expands Headquarters to Support Company Growth and Pipeline Innovation
Learn More >
Dec 13
2021
2021
Allogene Therapeutics Reports Positive Results from Phase 1 UNIVERSAL Study of Single Dose ALLO-715 AlloCAR T™ Cell Therapy in Relapsed/Refractory Multiple Myeloma at the 63rd American Society of Hematology Annual Meeting
Learn More >
Dec 13
2021
2021
Allogene Therapeutics Reports Positive Phase 1 Data from the ALPHA Trials in Non-Hodgkin’s Lymphoma at the 63rd Annual Meeting of the American Society of Hematology
Learn More >
Dec 01
2021
2021
Allogene Therapeutics Announces Conference Call to Review ALPHA, ALPHA2 and UNIVERSAL Phase 1 Data Presented at the 2021 American Society of Hematology Annual Meeting
Learn More >
Nov 12
2021
2021
Allogene Therapeutics Announces Participation in Five Upcoming Virtual Investor Conferences
Learn More >
Nov 04
2021
2021
Allogene Therapeutics Reports Third Quarter 2021 Financial Results and Business Update
Learn More >
Nov 04
2021
2021